<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130938">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01663077</url>
  </required_header>
  <id_info>
    <org_study_id>KBK2012</org_study_id>
    <secondary_id>03/11</secondary_id>
    <nct_id>NCT01663077</nct_id>
  </id_info>
  <brief_title>Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients</brief_title>
  <official_title>Clozapine Fixed Dose Steady State Plasma Levels and the Relationship to the Polymorphism of CYP1A2, CYP3A4, CYP3A5 and CYP2D6 in Clinically Stable Schizophrenic Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tirat Carmel Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technion, Israel Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ben-Gurion University of the Negev</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beersheva Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaâ€™ar Menashe Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Nazareth Hospital, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tirat Carmel Mental Health Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 30-60% of all schizophrenia patients who fail to respond to typical
      antipsychotics may respond to Clozapine. Clozapine has long been considered the &quot;gold
      standard&quot; within the atypical neuroleptic spectrum, backed by years of clinical experience
      and research, but uncertainties remain in some aspects of this drug. One such question is
      the link between dose, blood levels and patient clinical response. The Clozapine therapeutic
      plasma levels range between 250 - 450 ng/mL creating difficulties in using these results in
      routine clinical practice. Approximately 30% - 51% of &quot;treatment-resistant schizophrenia&quot;
      patients do not fully respond to Clozapine, a poorly understood phenomenon. Factors relevant
      to Clozapine-resistance include co-morbidity, drug misuse, poor adherence, inadequate
      duration of treatment and inadequate dose/plasma-levels. Pharmacogenetic factors such as
      different polymorphisms in involved genes may play a role. Pharmacodynamic and genetic data
      appear important in determining the clinical response to Clozapine. Clozapine-treated
      patients possessing different 3A4 polymorphisms, may respond differently as compared to
      other patients having normal 3A4 alleles. Recently, the CYP2D6 has also been involved in
      this drug metabolic pathway. Population pharmacokinetics of clozapine evaluated with the
      nonparametric maximum likelihood method. This pharmacogenetic explanation/hypothesis may
      explain Clozapine- resistance in schizophrenics.

      The high variability in plasma levels requires a large study in order to be able to
      determine correlation between clinical efficacy and plasma levels and genotyping. A
      preliminary study will enable power analysis and adequate determination of sample size.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clozapine steady state plasma level</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polymorphism  of CYP1A2, CYP3A4, CYP3A5 and CYP2D6 in clinically stable schizophrenic adult patients</measure>
    <time_frame>Once</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Clozapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clozapine tablet 150 mg at the day and 150 mg in the evening by mouth per day for 3 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month</description>
    <arm_group_label>Clozapine</arm_group_label>
    <other_name>Leponex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV criteria for schizophrenia (American Psychiatric Association 2000)

          -  All clozapine mono-therapy patients (only 300 mg/day) who respond to treatment and
             achieved symptomatic remission (45, 46) and were stable for at least 3 month will be
             included

          -  No change in benzodiazepine medications for the trial period.

          -  Legal ability and willingness to sign an informed consent form for participation in
             the study.

        Exclusion Criteria:

          -  Evidence of serious neurologic or endocrine disorder, for example severe head trauma,
             seizure disorder, dementia, Cushing's disease, thyroid disorder, mental retardation,
             alcohol or drug abuse, substance dependence (other than nicotine dependence), or
             presenting symptoms likely substance- induced, as judged by a study physician.

          -  Unstable medical illness or neurologic illness (seizures, CVA); breast, uterine, or
             ovarian cancer.

          -  Pregnant women, use of oral contraceptives or other hormonal supplementation such as
             estrogen. [Female patients will also have a pregnancy test.].
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anatoly Kreinin, MD, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Tirat Carmel Mental Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yedidia Bentur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus, Haifa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norberto Krivoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus, Haifa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Rabinowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus, Haifa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kamal Farhat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Nazareth Hospital-EMM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Lerner, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beersheva Mental Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boaz Bloch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haemek Hospital, Afula</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Grinshpoon, MD, MHA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaar Menashe MHC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anatoly Kreinin, MD, PhD</last_name>
    <phone>+97248559325</phone>
    <email>ANATOLY.KREININ@PSTIRA.HEALTH.GOV.IL</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tirat Carmel Mental Health Center</name>
      <address>
        <city>Tirat Carmel</city>
        <zip>30200</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anatoly Kreinin, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Anatoly Kreinin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>August 8, 2012</lastchanged_date>
  <firstreceived_date>July 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tirat Carmel Mental Health Center</investigator_affiliation>
    <investigator_full_name>Anatoly Dr. Kreinin</investigator_full_name>
    <investigator_title>Director of Psychiatric Department</investigator_title>
  </responsible_party>
  <keyword>Clozapine</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Remissia</keyword>
  <keyword>polymorphism</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
